Cytodyn Inc
Change company Symbol lookup
Select an option...
CYDY Cytodyn Inc
HRZN Horizon Technology Finance Corp
IZEA IZEA Worldwide Inc
HAIIF Haitian International Holdings Ltd
PM Philip Morris International Inc
CCLP CSI Compressco LP
CBWTF Auxly Cannabis Group Inc
FGPR Ferrellgas Partners LP
PFE Pfizer Inc
MSFT Microsoft Corp
Go

Health Care : Biotechnology |
Company profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Price
Delayed
$4.94
Day's Change
-0.034 (-0.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.08
Day's Low
4.70
Volume
(Light)

Today's volume of 2,657,708 shares is on pace to be much lighter than CYDY's 10-day average volume of 6,678,742 shares.

2,657,708

CytoDyn's stock falls after hitting roadblock in FDA application for investigational HIV drug

9:46 am ET July 13, 2020 (MarketWatch)
Print

Shares of CytoDyn Inc. (CYDY) fell 9.4% in trading on Monday after the company said it received a refusal to file letter from the Food and Drug Administration for its experimental HIV drug leronlimab. CytoDyn said in a news release that it is "confident it can provide all information requested by the FDA" and it believes that additional clinical trials will not be needed. CytoDyn's stock has gained 214.0% year-to-date, primarily driven by news that it is testing leronlimab as a treatment for COVID-19. The S&P 500 , in comparison, is down 1.4%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 13, 2020 09:46 ET (13:46 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.